Vernon K Sondak

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. ncbi Current status of biomarkers for melanoma metastasis
    Vernon K Sondak
    Division of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612, USA
    IDrugs 9:627-31. 2006
  2. ncbi Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Vernon K Sondak
    Division of Cutaneous Oncology, Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, Florida, USA
    Clin Cancer Res 12:2337s-2341s. 2006
  3. ncbi Advances in the understanding and treatment of melanoma -- Keystone Symposium
    Vernon K Sondak
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    IDrugs 9:157-60. 2006
  4. pmc Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?
    Dale Han
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 20:2345-51. 2013
  5. pmc Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm
    Dale Han
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 19:3335-42. 2012
  6. pmc The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms
    Kim H T Paraiso
    The Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Clin Cancer Res 18:2502-14. 2012
  7. pmc The unique clinical characteristics of melanoma diagnosed in children
    Dale Han
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 19:3888-95. 2012
  8. pmc Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin--a case-control study
    Michelle R Iannacone
    Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
    BMC Cancer 12:417. 2012
  9. pmc Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults
    Damon Reed
    Department of a Sarcoma Oncology, Moffitt Cancer Center, Tampa, Florida 33612, USA
    J Natl Compr Canc Netw 11:679-86. 2013
  10. pmc Single-institution outcome experience using AlloDerm® as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects
    JEREMIAH L DENEVE
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Am Surg 79:476-82. 2013

Collaborators

Detail Information

Publications123 found, 100 shown here

  1. ncbi Current status of biomarkers for melanoma metastasis
    Vernon K Sondak
    Division of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612, USA
    IDrugs 9:627-31. 2006
    ....
  2. ncbi Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
    Vernon K Sondak
    Division of Cutaneous Oncology, Department of Interdisciplinary Oncology, University of South Florida College of Medicine, Tampa, Florida, USA
    Clin Cancer Res 12:2337s-2341s. 2006
    ..Although allogeneic vaccines can be manufactured in sufficient quantities to allow large-scale trials, there remain significant limiting issues in the manufacture and standardization of the vaccine product...
  3. ncbi Advances in the understanding and treatment of melanoma -- Keystone Symposium
    Vernon K Sondak
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    IDrugs 9:157-60. 2006
  4. pmc Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?
    Dale Han
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 20:2345-51. 2013
    ..The utility of sentinel lymph node biopsy (SLNB) for desmoplastic melanoma (DM) is debated. We describe a large single-institution experience with SLNB for DM to determine clinicopathologic factors predictive of SLN metastasis...
  5. pmc Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm
    Dale Han
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 19:3335-42. 2012
    ..We describe a large single institution experience with SLNB for thin melanomas to determine factors predictive of nodal metastases...
  6. pmc The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms
    Kim H T Paraiso
    The Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Clin Cancer Res 18:2502-14. 2012
    ..The clinical use of BRAF inhibitors is being hampered by the acquisition of drug resistance. This study shows the potential therapeutic use of the HSP90 inhibitor (XL888) in six different models of vemurafenib resistance...
  7. pmc The unique clinical characteristics of melanoma diagnosed in children
    Dale Han
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 19:3888-95. 2012
    ..We describe a large single-institution experience with pediatric melanoma and assess prognostic characteristics...
  8. pmc Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin--a case-control study
    Michelle R Iannacone
    Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
    BMC Cancer 12:417. 2012
    ..Ultraviolet radiation (UVR) exposure is the most important environmental risk factor for NMSC. However, the precise relationship between UVR and the risk of NMSC is complex, and the relationship may differ by skin cancer type...
  9. pmc Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults
    Damon Reed
    Department of a Sarcoma Oncology, Moffitt Cancer Center, Tampa, Florida 33612, USA
    J Natl Compr Canc Netw 11:679-86. 2013
    ..This article provides data and weighs the pros and cons of a rationale for decision-making in pediatric and young adult patients with diagnostically challenging melanocytic lesions...
  10. pmc Single-institution outcome experience using AlloDerm® as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects
    JEREMIAH L DENEVE
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Am Surg 79:476-82. 2013
    ..In situations in which adjuvant radiation is needed, AlloDerm can be used without major complications...
  11. pmc Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
    Adil I Daud
    Cutaneous Oncology and Experimental Therapeutics Programs, H Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, USA
    J Clin Oncol 26:5896-903. 2008
    ..In vivo electroporation, in preclinical models, significantly enhances gene transfer efficiency while retaining the safety advantages of plasmid DNA...
  12. pmc Case-control study of cutaneous human papillomavirus infection in Basal cell carcinoma of the skin
    Michelle R Iannacone
    Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida 33647, USA
    J Invest Dermatol 133:1512-20. 2013
    ..In conclusion, the combined serology and tumor DNA results suggest that β HPV types may have a role in BCC. Additional studies of BCC that assess HPV types in multiple genera are needed...
  13. pmc Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin
    Michelle R Iannacone
    Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Epidemiol Biomarkers Prev 21:1303-13. 2012
    ..Cutaneous human papillomavirus (HPV) infection may be a risk factor for squamous cell carcinoma (SCC) of the skin...
  14. pmc Merkel cell carcinoma of unknown primary origin
    JEREMIAH L DENEVE
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 19:2360-6. 2012
    ..MCC from an unknown primary origin (MCCUP) can present a diagnostic and therapeutic challenge. We describe our single-institution experience with the diagnosis and management of MCCUP presenting as metastases to lymph nodes...
  15. doi Case-control study of smoking and non-melanoma skin cancer
    Dana E Rollison
    Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Causes Control 23:245-54. 2012
    ..To investigate the association between cigarette smoking and basal and squamous cell carcinomas (BCC and SCC) of the skin, a clinic-based case-control study was conducted in Tampa, FL...
  16. doi Full-thickness grafts procured from skin overlying the sentinel lymph node basin; reconstruction of primary cutaneous malignancy excision defects
    James M Lewis
    Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA
    Ann Surg Oncol 15:1733-40. 2008
    ..However, the potential for implantation of malignant cells transferred from the nodal basin to the primary site, resulting in increased perigraft recurrence rates with the FTSG technique, has not been evaluated...
  17. pmc Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma
    Gabriella M Anic
    Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA
    Cancer Epidemiol 37:434-9. 2013
    ..We examined the association between telomere length and skin cancer in a clinic-based case-control study of 198 melanoma cases, 136 squamous cell carcinoma (SCC) cases, 185 basal cell carcinoma (BCC) cases, and 372 healthy controls...
  18. pmc Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection
    JEREMIAH L DENEVE
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 20:307-12. 2013
    ..Cutaneous leiomyosarcoma is primarily a low-grade malignancy that affects elderly male Caucasians. It is a rare dermal-based tumor for which treatment algorithms have been poorly defined...
  19. doi Adjuvant therapy for melanoma: a surgical perspective
    Vernon K Sondak
    Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Surg Oncol Clin N Am 20:105-14. 2011
    ..This review summarizes the potential oncologic benefits and relevant toxicities of adjuvant systemic therapies for melanoma that are currently available and under investigation...
  20. pmc Is a Wider Margin (2 cm vs. 1 cm) for a 1.01-2.0 mm Melanoma Necessary?
    Matthew P Doepker
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 23:2336-42. 2016
    ..01 and 2 mm deep is a 1-2 cm radial margin. We sought to determine whether margin width had an impact on local recurrence (LR), disease-specific survival (DSS), and type of wound closure...
  21. pmc Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma
    H Eirik Haarberg
    Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Mol Cancer Ther 12:901-12. 2013
    ..Together, these studies have identified Wee1 as a key target of XL888, suggesting novel therapeutic strategies for NRAS-mutant melanoma...
  22. pmc Radiotherapy influences local control in patients with desmoplastic melanoma
    Tobin Strom
    Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida
    Cancer 120:1369-78. 2014
    ..The authors hypothesized that adjuvant radiotherapy (RT) would improve local control in patients with desmoplastic melanoma, resulting in at least a 10% absolute decrease in local recurrence rate...
  23. pmc Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma
    Vernon K Sondak
    H Lee Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 20:680-8. 2013
    ..99m)Tc]Tilmanocept is a CD206 receptor-targeted radiopharmaceutical designed for sentinel lymph node (SLN) identification. Two nearly identical nonrandomized phase III trials compared [(99m)Tc]tilmanocept to vital blue dye...
  24. pmc 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?
    Jane L Messina
    Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA the Departments of Pathology and Cell Biology, University of South Florida, Tampa, FL, USA
    Sci Rep 2:765. 2012
    ....
  25. pmc Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin
    Michelle R Iannacone
    Department of Cancer Epidemiology, College of Medicine, University of South Florida, Tampa, Florida, USA
    J Infect Dis 206:399-406. 2012
    ..Ultraviolet radiation exposure may interact synergistically with cutaneous human papillomavirus (HPV) infection in the development of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin...
  26. doi Current and planned multicenter trials for patients with primary or metastatic melanoma
    Vernon K Sondak
    The Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA
    J Surg Oncol 104:430-7. 2011
    ..The purpose of this review is to summarize relevant ongoing and planned multicenter trials that have and continue to define current melanoma management...
  27. ncbi Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma
    Amod A Sarnaik
    Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Control 16:240-7. 2009
    ..Improved understanding is needed regarding the factors predisposing patients to complications and the operative and perioperative maneuvers that can decrease morbidity...
  28. doi Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma
    Tobin Strom
    Department of Radiation Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Ann Surg Oncol 23:3572-8. 2016
    ..Controversy remains as to whether RT can be avoided in selected cases, such as those with negative margins. Additionally, there is evidence that RT can influence survival...
  29. pmc Cutaneous angiosarcoma: a single-institution experience
    Matthew C Perez
    Morsani College of Medicine, University of South Florida, Tampa, FL, USA
    Ann Surg Oncol 20:3391-7. 2013
    ..Cutaneous angiosarcoma (CAS) is a rare, aggressive vascular sarcoma with a poor prognosis, historically associated with 5-year overall survival (OS) rates between 10 and 30 %...
  30. pmc Identifying risk factors using a skin cancer screening program
    Jeremy R Etzkorn
    University of South Florida, College of Medicine, Department of Dermatology and Cutaneous Surgery, Tampa, FL 33612, USA
    Cancer Control 20:248-54. 2013
    ..This study details the relationship of a group of well-known risk factors with presumptive diagnoses in a large series of individuals self-referred for free skin cancer screening...
  31. ncbi Treatment options for limited or symptomatic metastatic melanoma
    James M McLoughlin
    Cutaneous Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:239-47. 2008
    ..Patients who develop metastatic melanoma often have limited effective treatment options. However, a select group of patients will benefit from aggressive surgery or a multidisciplinary approach, depending on the site of metastasis...
  32. ncbi Sentinel lymph node biopsy for melanoma: indications and rationale
    Giao Q Phan
    Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Control 16:234-9. 2009
    ..Sentinel lymph node biopsy (SLNB) was developed as a technique to surgically assess the regional lymph nodes and spare node-negative patients unnecessary and potentially morbid complete lymphadenectomies...
  33. pmc In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma
    Narges K Tafreshi
    Department of Cancer Imaging and Metabolism, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, United States
    Mol Pharm 10:3175-85. 2013
    ..The process of cell-surface marker validation, targeted imaging probe development, and in vitro, in vivo, and in silico characterization described in this study can be generally applied to preclinical development of targeted agents. ..
  34. doi Integrating molecular biomarkers into current clinical management in melanoma
    Ragini Kudchadkar
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Methods Mol Biol 1102:27-42. 2014
    ..As further research helps clarify the roles of these factors, the clinical outcomes of melanoma patients promise to be greatly improved...
  35. ncbi Novel treatments for melanoma brain metastases
    Rajappa S Kenchappa
    Department of Neuro Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 20:298-306. 2013
    ..Treating patients with melanoma brain metastases (MBMs) is a major therapeutic challenge. Standard approaches with conventional chemotherapy are disappointing, while surgery and radiotherapy have improved outcomes...
  36. doi Targeted therapy in melanoma
    Ragini R Kudchadkar
    Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Clin Dermatol 31:200-8. 2013
    ..We discuss the toxicities of targeted agents in use for melanoma, in particular the dermatologic effects and the management of these skin toxicities...
  37. doi Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients
    Omie L Mills
    Department of Pathology and Cell Biology, College of Medicine, University of South Florida, Tampa, FL 33612, USA
    J Cutan Pathol 39:331-6. 2012
    ..We herein report our institutional experience with SLNB in pediatric patients with these lesions, hereafter referred to as 'atypical melanocytic proliferations'...
  38. pmc Case-control study of Merkel cell polyomavirus infection and cutaneous squamous cell carcinoma
    Dana E Rollison
    Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33647, USA
    Cancer Epidemiol Biomarkers Prev 21:74-81. 2012
    ..Merkel cell polyomavirus (MCV) DNA has been reported in 0% to 25% of squamous cell carcinomas (SCC) occurring in immunocompetent individuals. We conducted the first serologic case-control study of MCV and SCC...
  39. doi Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
    Adil I Daud
    H Lee Moffitt Cancer Center, Tampa, FL, USA
    J Clin Oncol 26:3235-41. 2008
    ..We hypothesized that GM-CSF-stimulated DC differentiation may result in clinical benefit in patients with high-risk melanoma...
  40. pmc Shave biopsy is a safe and accurate method for the initial evaluation of melanoma
    Jonathan S Zager
    Department of Cutaneous Oncology, Moffitt Cancer Center, and the University of South Florida College of Medicine, Tampa, FL 33612, USA
    J Am Coll Surg 212:454-60; discussion 460-2. 2011
    ..However, this technique has been criticized for its potential to hamper accurate diagnosis and microstaging of melanoma, thereby complicating treatment decision-making...
  41. doi Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck
    Tobin Strom
    Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Head Neck . 2016
    ..We hypothesized that radiotherapy (RT) would improve both local and regional control with Merkel cell carcinoma of the head and neck...
  42. pmc Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy
    Matthew P Doepker
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida
    J Surg Oncol 113:98-102. 2016
    ..We sought to investigate the natural history of DM and the utility and prognostic significance of sentinel lymph node biopsy (SLNB)...
  43. pmc Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience
    Nicholas DeVito
    Sarcoma Department, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America
    PLoS ONE 10:e0140362. 2015
    ..While surgery appears to be the best treatment option for benign and malignant SFT, better systemic therapies are needed to improve outcomes of patients with metastatic, malignant SFT. ..
  44. pmc Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma
    Vito W Rebecca
    Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Pigment Cell Melanoma Res 27:465-78. 2014
    ..We demonstrate for the first time that AKT inhibition in combination with chemotherapy may have clinical activity in BRAF WT melanoma and show that an autophagy inhibitor may prevent resistance to these drugs...
  45. pmc Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma
    Geoffrey T Gibney
    Department of Cutaneous Oncology, The Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Nat Rev Clin Oncol 10:390-9. 2013
    ....
  46. pmc Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression
    Jong Y Park
    Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Epidemiol Biomarkers Prev 22:827-34. 2013
    ..We investigated associations between genetic variants in these pathways with sentinel lymph node (SLN) metastasis and mortality in 2 independent series of patients with melanoma...
  47. ncbi Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
    Vernon K Sondak
    H Lee Moffitt Cancer Center and University of South Florida College of Medicine, Tampa, FL 33612, USA tt org
    Lancet 372:89-90. 2008
  48. doi Melanoma in the brain: biology and therapeutic options
    Geoffrey Thomas Gibney
    Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida 33612, USA
    Melanoma Res 22:177-83. 2012
    ..In this review, we discuss the biology of brain metastases in metastatic melanoma, current treatment approaches with surgery and radiotherapy, and future systemic therapeutic strategies...
  49. doi Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma
    David J Casper
    Department of Dermatology, University of South Florida, Tampa, FL, USA
    Am J Dermatopathol 32:650-4. 2010
    ..Subsequent studies will be needed confirm the accuracy of this staining technique, which has the potential to be used as a screening method for counting MFs before conventional H&E methodology in the microstaging of thin melanoma...
  50. ncbi Sentinel lymph node biopsy as the standard of care for cutaneous melanoma
    Vernon K Sondak
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL 33612, USA
    Clin Adv Hematol Oncol 5:483-90. 2007
  51. doi CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues
    Giao Q Phan
    Division of Cutaneous Oncology, H Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Ann Surg Oncol 15:3014-21. 2008
    ..CTLA-4 blockade by means of monoclonal antibodies (ipilimumab and tremelimumab) has been evaluated in multiple clinical trials in patients with metastatic cancer, mainly those with melanoma and renal cell cancer...
  52. ncbi Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma
    Eric H Jensen
    Department of Interdisciplinary Oncology, Cutaneous Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Stabile Research Building, Room 22043, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Ann Surg Oncol 14:1416-23. 2007
    ..We used cDNA microarray to evaluate pro-apoptotic gene expression comparing normal skin to melanoma (thin and thick), nodal disease and distant metastases...
  53. doi The role of radiation therapy in the management of cutaneous melanoma
    Nikhil G Rao
    Department of Radiation Oncology, H Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Surg Oncol Clin N Am 20:115-31. 2011
    ..Emerging technology such as stereotactic radiation therapy may be useful in achieving durable palliation for selected patients...
  54. ncbi Cutaneous melanoma: methods of biopsy and definitive surgical excision
    Adam I Riker
    Cutaneous Oncology Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, 33612, USA
    Dermatol Ther 18:387-93. 2005
    ..The present authors review current recommendations for excision margins for the primary tumor, usefulness of lymphoscintigraphy, timing of definitive surgical excision, and issues unique for head and neck melanoma...
  55. pmc Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma
    Franz O Smith
    Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida
    Cancer 121:3252-60. 2015
    ....
  56. pmc Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype
    Kim H T Paraiso
    Department of Molecular Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida
    Cancer Discov 5:264-73. 2015
    ..We suggest that inhibition of ligand-independent EPHA2 signaling may limit metastases associated with BRAF inhibitor therapy...
  57. pmc Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray
    Charles F Knapp
    Department of Dermatology, University of South Florida College of Medicine, Tampa, FL 33612 4272, USA
    Am J Dermatopathol 34:592-6. 2012
    ..Further discovery of additional markers are needed to better characterize this rare but deadly malignancy...
  58. pmc Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma
    Shari Pilon-Thomas
    Donald A Adam Comprehensive Melanoma Research Center, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Immunother 35:615-20. 2012
    ..Adoptive therapy with infiltrating lymphocytes is labor intensive but feasible and has a high response rate in treated patients...
  59. doi Surgical management of melanoma-in-situ using a staged marginal and central excision technique
    Mecker G Möller
    Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Ann Surg Oncol 16:1526-36. 2009
    ..This reinforces the importance of adequate full-thickness biopsies of suspicious pigmented lesions before any type of surgical management. With short follow-up, local control has been achieved by this technique in 100% of cases...
  60. doi Management of familial melanoma and nonmelanoma skin cancer syndromes
    Alfredo A Santillan
    Division of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA
    Surg Oncol Clin N Am 18:73-98, viii. 2009
    ..This article discusses a practical approach for some of the issues likely encountered by the surgeon in the management of familial melanoma and non-melanoma skin cancer...
  61. ncbi Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database
    M Aleem Khan
    Department of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 13:211-7. 2006
    ..Since few trials in melanoma have had a non-treated cohort, it remains unclear what survival can be expected in patients who are not treated with chemotherapy...
  62. doi Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers
    Dana E Rollison
    Division of Cancer Prevention and Control, Moffitt Cancer Center, Tampa, FL, USA
    Int J Cancer 123:2337-42. 2008
    ..Based on the current case series, the combinations of antibodies+eyebrow hairs or antibodies+eyebrow hairs+Dacron swabs are the optimal, minimally invasive markers of cutaneous HPV infection for use in epidemiologic studies...
  63. ncbi Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites
    Amod A Sarnaik
    Division of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Department of Interdisciplinary Oncology, University of South Florida College of Medicine, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Curr Oncol Rep 9:417-27. 2007
    ....
  64. ncbi Unanswered questions in the management of stage I-III Merkel cell carcinoma
    Jonathan S Zager
    From the aDepartment of Cutaneous Oncology, H Lee Moffitt Cancer Center bDepartment of Oncologic Sciences, University of South Florida Morsani College of Medicine and cDepartment of Anatomic Pathology, H Lee Moffitt Cancer Center, Tampa, Florida
    J Natl Compr Canc Netw 12:425-31; quiz 431. 2014
    ..The intent, however, is not to exhaustively identify all areas of controversy, but rather to highlight clinically relevant questions that further studies could address to improve the standard of care for MCC. ..
  65. doi Targeted therapy for melanoma: is double hitting a home run?
    Keiran S M Smalley
    Department of Molecular Oncology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Nat Rev Clin Oncol 10:5-6. 2013
    ..This trial provides strong support for developing combinations hitting the same pathway in melanoma...
  66. pmc A brief history of melanoma: from mummies to mutations
    Vito W Rebecca
    Department of Molecular Oncology, The Moffitt Cancer Center, Tampa, Florida 33612, USA
    Melanoma Res 22:114-22. 2012
    ..We further outline how observations about melanoma heterogeneity, first made over 190 years ago, continue to drive our efforts to reduce melanoma to the level of a chronic, manageable disease and ultimately to cure it entirely...
  67. pmc Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients
    Steven E Finkelstein
    H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Int J Radiat Oncol Biol Phys 82:924-32. 2012
    ....
  68. doi Multimodality management of desmoid tumors: how important is a negative surgical margin?
    Marcovalerio Melis
    Division of Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    J Surg Oncol 98:594-602. 2008
    ..We reviewed the current evidence for multimodality therapy of desmoids, with a focus on the importance of resection margins, and present our own algorithm for treatment...
  69. doi Targeted therapies: Improved outcomes for patients with metastatic melanoma
    Vernon K Sondak
    Department of Cutaneous Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Nat Rev Clin Oncol 8:513-5. 2011
    ..All three therapies are potential first-line options for patients with metastatic melanoma, with optimal treatment strategies evolving based on tumor mutation status, disease burden, performance status and comorbidities...
  70. pmc Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand
    Narges K Tafreshi
    Department of Cancer Imaging and Metabolism, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Bioconjug Chem 23:2451-9. 2012
    ..05). In conclusion, the MC1R-specific imaging probe developed in this study displays excellent potential for the intraoperative detection of regional node involvement and for margin detection during melanoma metastasis resection...
  71. ncbi Unanswered questions about margin recommendations for primary cutaneous melanoma
    Joyce Y Wong
    Department of Cutaneous Oncology, H Lee Moffitt Cancer Center, University of South Florida College of Medicine, Tampa, Florida 33612, USA
    J Natl Compr Canc Netw 10:357-65. 2012
    ..This article addresses current uncertainty surrounding optimal margin status in primary cutaneous melanoma...
  72. pmc PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression
    Kim H T Paraiso
    Department of Molecular Oncology, The Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida, USA
    Cancer Res 71:2750-60. 2011
    ..In conclusion, we have shown for the first time that loss of PTEN contributes to intrinsic BRAF inhibitor resistance via the suppression of BIM-mediated apoptosis...
  73. ncbi c-KIT signaling as the driving oncogenic event in sub-groups of melanomas
    Keiran S M Smalley
    The Comprehensive Melanoma Research Center and the Department of Cutaneous Oncology, The Moffitt Cancer Center, Tampa, FL, USA
    Histol Histopathol 24:643-50. 2009
    ..The current review discusses the role of c-KIT signaling in melanoma progression and how this new information can be applied to the targeted therapy of melanoma...
  74. ncbi Sentinel node biopsy for thin melanomas: which patients should be considered?
    Christopher A Puleo
    Cutaneous Oncology Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 12:230-5. 2005
    ..Currently available prognostic factors are limited in their ability to reliably discriminate which patients will manifest regional nodal metastasis and would be identified early through sentinel node biopsy...
  75. ncbi Ipilimumab
    Vernon K Sondak
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA
    Nat Rev Drug Discov 10:411-2. 2011
    ....
  76. ncbi Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas
    Audrey C Shor
    Sarcoma Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:47-54. 2008
    ..Sarcomas are rare mesenchymally derived tumors for which there are limited treatment options. This paper discusses the current therapeutic potential of directed tyrosine kinase inhibitors (TKIs) in sarcoma...
  77. ncbi Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine
    Vernon K Sondak
    Division of Surgical Oncology, University of Michigan Health System, 3306 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 0932, USA
    Semin Cancer Biol 13:409-15. 2003
    ..A phase III trial indicated a survival benefit for Melacine in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. This finding must now be prospectively confirmed...
  78. ncbi Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model
    Vernon K Sondak
    Department of Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA
    Ann Surg Oncol 11:247-58. 2004
    ..Several factors have been variably, and sometimes discordantly, reported to have predictive value for SLN metastasis to best select which patients require SLN biopsy...
  79. ncbi A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study
    Robert P Whitehead
    University of Texas Medical Branch, Galveston, Texas, USA
    Cancer 100:1699-704. 2004
    ..In the current study, the authors evaluated the antitumor effects and toxicity of vinorelbine therapy in patients who had failed one prior systemic therapy...
  80. ncbi Desmoplastic and neurotropic melanoma
    Lyndon D Su
    Department of Pathology, University of Michigan Medical Center, Ann Arbor, Michigan48109 0602, USA
    Cancer 100:598-604. 2004
    ..The value of sentinel lymph node biopsy (SLNB) has not been demonstrated clearly for patients with DNMM. The authors report on the utility of SLNB in the management of patients with DNMM...
  81. ncbi Metastatic nevoid melanoma in a 4 1/2-year-old child
    David S Cassarino
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Cutan Pathol 30:647-51. 2003
    ..Childhood melanoma is a rare and controversial diagnosis...
  82. ncbi Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts
    Timothy M Johnson
    Department of Dermatology, University of Michigan Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor 48109 0314, USA
    Arch Dermatol 140:107-13. 2004
    ..To clarify and update workup and follow-up strategies based on fundamental principles and current data, and to discuss new and current concepts regarding sentinel lymph node biopsy (SLNB), particularly in relation to the staging workup...
  83. ncbi When will melanoma vaccines be proven effective?
    Jeffrey A Sosman
    J Clin Oncol 22:387-9. 2004
  84. ncbi Melacine: an allogeneic melanoma tumor cell lysate vaccine
    Jeffrey A Sosman
    Melanoma Program, Vanderbilt Ingram Cancer Center, Division of Hematology Oncology, Nashville, TN 37027, USA
    Expert Rev Vaccines 2:353-68. 2003
    ..This finding must now be confirmed in a large perspective observation-controlled clinical trial to solidify the role of Melacine as an effective cancer vaccine in melanoma...
  85. ncbi The sentinel lymph node: more than just another blue lymph node
    Jeffrey D Wagner
    Cancer 97:1821-3. 2003
  86. ncbi Melanoma: adjuvant therapy and other treatment options
    Alicia Terando
    University of Michigan Comprehensive Cancer Center, 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Curr Treat Options Oncol 4:187-99. 2003
    ....
  87. ncbi Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma
    Jeffrey Weber
    Department of Medicine, Division of Medical Oncology, Keck University of Southern California School of Medicine, Los Angeles, CA, USA
    Cancer 97:186-200. 2003
    ..Time to recurrence and survival were secondary end points...
  88. ncbi Melanoma vaccines: breakthrough or bust?
    Michael S Sabel
    Cancer Invest 20:1114-6. 2002
  89. ncbi Tumor vaccines: a role in preventing recurrence in melanoma?
    Michael S Sabel
    University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    Am J Clin Dermatol 3:609-16. 2002
    ....
  90. ncbi Melanoma and human leukocyte antigen status: the missing link?
    Vernon K Sondak
    Ann Surg Oncol 9:723-4. 2002
  91. ncbi How does interferon work? Does it even matter?
    Vernon K Sondak
    Cancer 95:947-9. 2002
  92. ncbi Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome
    Jeffrey A Sosman
    Vanderbilt University, Nashville, TN, USA
    J Clin Oncol 20:2067-75. 2002
    ..This study investigated whether class I antigen expression impacted relapse-free survival (RFS) after adjuvant therapy with this vaccine...
  93. ncbi Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma
    Timothy S Wang
    Department of Dermatology, University of Michigan Health System, University of Michigan Comprehensive Cancer Center, USA
    J Am Acad Dermatol 51:399-405. 2004
    ..Radiographic and laboratory evaluations are often routinely used in the initial work-up for melanoma...
  94. ncbi Melanoma margins: the importance and need for more evidence-based trials
    Timothy M Johnson
    Department of Dermatology, University of Michigan Medical School, Ann Arbor 48109 0314, USA
    Arch Dermatol 140:1148-50. 2004
  95. ncbi Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026
    Laura F Hutchins
    Division of Hematology Oncology, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
    Cancer 110:2269-75. 2007
    ..Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma. Endpoints were 6-month progression-free survival rate, response rate, and toxicity...
  96. ncbi The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma
    Sandra C Paek
    Department of Dermatology, University of Michigan Health System, Ann Arbor, Michigan, USA
    Cancer 109:100-8. 2007
    ..The objectives of the current study were to verify those previous results and to create a prediction model for the better selection of which patients with melanoma should undergo SLN biopsy...
  97. doi Lymphangiogenesis: host and tumor factors in nodal metastasis
    Vernon K Sondak
    Arch Dermatol 144:536-7. 2008
  98. ncbi The role of sentinel lymph node biopsy for melanoma: evidence assessment
    Timothy M Johnson
    Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    J Am Acad Dermatol 54:19-27. 2006
  99. ncbi Use and abuse of statistics in evidence-based medicine
    John M Kirkwood
    J Clin Oncol 20:4122-3; author reply 4123-4. 2002
  100. doi State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA
    Cancer 113:1728-43. 2008
  101. ncbi Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma
    Michael S Sabel
    Department of Surgery, University of Michigan Health System, Ann Arbor, MI 48109 0932, USA
    J Am Coll Surg 201:37-47. 2005
    ..We sought to assess predictive factors associated with finding positive NSLNs, and identify a subset of patients with low likelihood of finding additional disease on CLND...